FORUM REVIEW ARTICLE

Targeting Inflammation and Oxidative Stress in Atrial Fibrillation: Role of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibition with Statins

Ana Catarina Pinho-Gomes,¹ Svetlana Reilly,¹ Ralf P. Brandes,² and Barbara Casadei¹

Abstract

Significance: Atrial fibrillation (AF) is a burgeoning health-care problem, and the currently available therapeutic armamentarium is barely efficient. Experimental and clinical evidence implicates inflammation and myocardial oxidative stress in the pathogenesis of AF. **Recent Advances:** Local and systemic inflammation has been found to both precede and follow the new onset of AF, and NOX2-dependent generation of reactive oxygen species in human right atrial samples has been independently associated with the occurrence of AF in the postoperative period in patients undergoing cardiac surgery. Anti-inflammatory and antioxidant agents can prevent atrial electrical remodeling in animal models of atrial tachypacing and the new onset of AF after cardiac surgery, suggesting a causal relationship between inflammation/oxidative stress and the atrial substrate that supports AF. **Critical Issues:** Statin therapy, by redressing the myocardial nitroso-redox balance and reducing inflammation, has emerged as a potentially effective strategy for the prevention of AF. Evidence indicates that statins prevent AF-induced electrical remodeling in animal models of atrial tachypacing and may reduce the new onset of AF after cardiac surgery. However, whether statins have antiarrhythmic properties in humans has yet to be conclusively demonstrated, as data from randomized controlled trials specifically addressing the relevance of statin therapy for the primary and secondary prevention of AF remain scanty. **Future Directions:** A better understanding of the mechanisms underpinning the putative antiarrhythmic effects of statins may afford tailoring AF treatment to specific clinical settings and patient's subgroups. Large-scale randomized clinical trials are needed to support the indication of statin therapy solely on the basis of AF prevention. *Antioxid. Redox Signal.* 20, 1268–1285.

Introduction

ATRIAL FIBRILLATION (AF) is a heart rhythm disturbance that is characterized by rapid, irregular electrical and mechanical activation of the atria, which causes uncoordinated contraction and favors the formation of atrial thrombi. AF is an increasing health-care burden, because of the aging population and improved survival from acute cardiovascular events, such as myocardial infarction. The lifetime risk for development of AF in all men and women older than 40 is estimated at about 25%; whereas for those without previous or concurrent cardiovascular events, the lifetime risk is 16% (60, 98). The presence of AF independently increases the risk of mortality and morbidity, mostly due to stroke and heart

failure (HF), resulting in disability and high health-care cost (24, 92). AF is often associated with a number of cardiac and noncardiac risk factors, including ischemic heart disease, HF, valvular heart disease, hypertension, diabetes, alcohol abuse, thyroid disorders, and pulmonary disease (1, 50), and it is present in 3%–6% of acute medical admissions, in which the most common comorbidities are coronary artery disease and HF (24). AF is also a common postoperative complication, especially after cardiothoracic surgery (70).

Clinically, AF can be divided into paroxysmal, persistent, and permanent (24). Paroxysmal AF is defined as recurrent (two or more) episodes of AF that terminate spontaneously in <7 days, usually <24 h; whereas persistent AF describes AF episodes lasting beyond 7 days. AF is regarded as permanent

¹Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.

²Vascular Research Center, Institute of Cardiovascular Physiology, Goethe University, Frankfurt, Germany.

when attempts to restore sinus rhythm have failed or have been deemed inappropriate and both patient and physician accept AF as the underlying rhythm of choice. It is important to stress that the decision to label AF as permanent reflects a (potentially reversible) management choice rather than a separate pathophysiological entity.

The mechanisms underlying the new onset of AF are hitherto only partially characterized, and the progression from paroxysmal to persistent AF as well as the factors responsible for the individual response to treatment are even further from being completely understood. In keeping with this, the pharmaceutical armamentarium currently available aims at controlling symptoms and at reducing the thromboembolic risk, the latter with agents that carry a significant risk of hemorrhagic events. The advantage of rhythm *versus* rate control remains a matter of debate (119), whereas the efficacy and safety of antiarrhythmic drugs used for the treatment of AF is an ongoing concern (74). Besides relieving symptoms, the main aim of the medical management of AF is to reduce the risk of thromboembolic stroke; however, the widely used clinically derived risk scores are not very accurate in predicting which patients with AF would benefit more from anticoagulant prophylaxis.

In view of these issues, the development of safer antiarrhythmic therapies targeted to the pathogenic mechanisms that are responsible for the initiation and perpetuation of AF would seem particularly important. In addition, a deeper insight into the pathogenesis of AF might refine the risk prediction scores for thromboembolic complications. In this context, several experimental and clinical studies have addressed the link between AF, inflammation, and oxidative stress.

Inflammation, Oxidative Stress, and AF: Cause or Effect?

A causal role of inflammation in the initiation of AF is suggested by the observation that inflammatory states, such as myocarditis, pericarditis, and cardiac surgery, are frequently associated with AF (113, 149). The first piece of evidence directly linking inflammation to AF was the histological findings of atrial myocarditis in patients with lone AF, but not in subjects with sinus rhythm (49). These findings were later confirmed in animal studies (146). However, cardiac surgery and cardiopulmonary bypass (CPB) have probably provided the strongest evidence linking a systemic inflammatory response to the new onset of AF after cardiac surgery. This is further reinforced by the observation that the postoperative peak in inflammatory markers, namely serum C-reactive protein (CRP) and interleukin 6 (IL-6), coincides with the peak incidence of AF (*i.e.*, at the 2–3 day after surgery) (21); whereas the milder systemic inflammatory response observed in patients undergoing coronary revascularisation off-pump is paralleled by a lower incidence of postoperative AF (6, 30). Moreover, preoperative levels of circulating cytokines (10) and the activity of a gp91-containing NADPH oxidase (NOX2) (76) in atrial tissue samples obtained at the time of CPB have also been independently associated with the new onset of postoperative AF and other in-hospital complications in patients undergoing cardiac surgery (9) (Fig. 1). These findings suggest that myocardial NOX2 activity preceding cardiac surgery,

inflammation, and ischemia/reperfusion injury may contribute to the pathogenesis of postoperative AF and help in refining risk stratification of these patients.

Chung *et al.* were the first to report an association between AF and elevated CRP (32). In this case-control study, CRP level was more than two-fold higher in patients with AF compared with controls. The association between elevated CRP and presence of AF was further supported by large population-based cohort studies. In 5806 elderly individuals followed for a mean of 6.9 years, CRP was associated with the presence of AF; whereas in patients with sinus rhythm, elevated CRP levels were independently associated with the future development of AF (13). In another study, 1 mg/dl increase in serum CRP was associated with a seven-fold increase in the risk of recurrent AF and a 12-fold increase in the risk of permanent AF (39). A meta-analysis of seven prospective observational studies, including 420 patients (229 with and 191 without AF relapse), indicated that increased baseline CRP levels are also associated with a greater risk of AF recurrence after successful cardioversion (standardized mean difference=0.35 units, 95% CI: 0.01–0.69) (94). Furthermore, a meta-analysis of six prospective studies, including 366 patients with AF who underwent cardioversion, found CRP levels to be higher in patients who failed to recover from sinus rhythm (Fig. 2), suggesting that CRP assessment may provide prognostic information on the success of this procedure (95, 100).

Besides CRP, other circulating inflammatory biomarkers, such as IL-6, IL-8, IL-1b, tumor necrosis factor- α (TNF- α), fibrinogen, and complement factors, have been independently associated with either incident or prevalent AF (21, 96, 127, 132, 139, 140). Indeed, in the Women's Health Study, a combined "inflammation score," including high sensitivity CRP, soluble intercellular adhesion molecules, and fibrinogen, independently predicted the new onset of AF over a median follow up of 14.4 years in 24,734 middle-aged women free of overt cardiovascular disease or cancer at baseline (34) (Fig. 3). However, patients who develop persistent AF are more likely to have undetected asymptomatic paroxysmal AF, which, in turn, might cause an increase in inflammatory markers. This raises the possibility that inflammation may be a consequence or a biomarker of AF rather than a causal mechanism (35). Indeed, restoration of sinus rhythm (either through pulmonary vein isolation or cardioversion) has been associated with reduction in CRP levels and improvement of endothelial function (71, 173). Conversely, AF induction in patients with paroxysmal AF undergoing ablation while in sinus rhythm has been associated with a rapid increase in soluble CD40 ligand (a member of the TNF α superfamily with pro-inflammatory and pro-thrombotic actions)(7) and in the endogenous nitric oxide synthase (NOS) inhibitor, asymmetric dimethylarginine (ADMA), when compared with patients who were paced at 150 beats per minute or patients with normal sinus rhythm. Both rapid pacing and AF induction increased platelet activation and thrombin generation, particularly in the left atrium, but AF also led to endothelial dysfunction and activation of the inflammatory cascade (91), suggesting that rapid atrial activation and altered blood flow are sufficient to elicit inflammation and increase pro-thrombotic risk. While the chicken or the egg causality dilemma remains, both are likely to be relevant, so that pre-existing inflammation paves the way for the initiation of AF, which, in turn, generates an

FIG. 1. Right atrial (RA) NADPH-stimulated superoxide production (an index of NOX2 activity) is independently associated with an increased risk of postoperative atrial fibrillation (AF) (A) and longer in-hospital stay (B) in patients undergoing elective cardiac surgery. Hazard ratio (HR [95% confidence interval (CI)]). *p* value derived from the Cox regression, after adjustment for age, use of beta-blockers, EuroSCORE (European System for Cardiac Operative Risk Evaluation), and postoperative AF (in B only). Three-day treatment with atorvastatin (atorva) 40 mg once daily decreases RA NADPH-stimulated superoxide production in statin-naïve patients undergoing cardiac surgery in a randomized, placebo-controlled comparison (C). ***p* < 0.01 versus placebo; RLU, relative light units. Modified from Antoniadou *et al.* (8). To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

inflammatory response that enhances atrial remodeling, thus facilitating the persistence of AF (Fig. 4).

How Do Inflammation and Oxidative Stress Induce an Arrhythmogenic Substrate?

A current understanding of the mechanisms by which inflammation (systemic or local) may lead to AF remains fairly limited. Rapid atrial activation in AF results in myocytes calcium overload (55), which, in turn, can lead to cardiomyocyte apoptosis and myolysis (4). The resulting cellular

damage induces a low-grade inflammatory response, which contributes to atrial structural remodeling. Inflammation-induced structural alterations in AF are supported by evidence of neutrophil infiltrates, cardiomyocyte necrosis and apoptosis, and fibrosis in atrial biopsies (49, 171) (Fig. 4). In a canine model, acute inflammation anisotropically slowed atrial conduction in response to programmed electrical stimulation, thus setting the stage for re-entry (155). Similarly, inhomogeneous atrial conduction and increased AF susceptibility were correlated with atrial neutrophil-derived myeloperoxidase (MPO) activity (*r* = 0.851, *p* < 0.001) in a canine

FIG. 2. C-reactive protein (CRP) levels are higher in patients with AF who fail electrical cardioversion. *df* = degrees of freedom; SMD = standardized mean difference. Reprinted with permission from Liu *et al.* (94). To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

FIG. 3. Cumulative incidence of incident AF by inflammation score. The inflammation score, which included high-sensitivity CRP, soluble intercellular adhesion molecules, and fibrinogen, partitioned 24,734 middle-aged women free of overt cardiovascular disease or cancer at baseline into four groups with a proportionally higher risk of incident AF, and independently predicted the new-onset AF over a median follow up of 14.4 years. Reprinted with permission from Conen *et al.* (34).

model of atriectomy or pericardiectomy (67). In the same model, anti-inflammatory therapy with methylprednisolone significantly decreased both MPO activity and the inhomogeneity of atrial conduction, thus supporting a role for neutrophil-derived inflammation in generating the atrial substrate for AF. Patients with AF have higher MPO plasma levels and a larger MPO burden in right atrial (RA) samples compared with individuals with sinus rhythm (133). Interestingly, MPO not only represents a marker of leucocyte infiltration but also appears to be causal for disease development, as MPO-deficient mice were protected from atrial fibrosis and AF susceptibility induced by angiotensin II infusion (133). Collectively, these findings indicate that inflammation-driven oxidative stress plays an important role in atrial structural remodeling.

Whether inflammation, and the resulting atrial oxidative stress, also affects atrial action potential duration (APD) and refractoriness or triggers activity from the pulmonary veins remains largely unknown. A number of sarcolemmal ionic currents have been shown to be directly or indirectly modulated by NO or reactive oxygen species (ROS) (162); however, the relevance of these mechanisms in the context of human AF remains to be conclusively demonstrated.

ROS also increase cardiac ryanodine receptor (RyR2) open probability by increasing the channel's sensitivity to cytosolic Ca and adenosine triphosphate (ATP) (43, 106), as well as by disrupting the interaction of RyR2 with triadin (93) and

FIG. 4. Schema illustrating the role of acute and low-grade inflammation in AF. Inflammatory conditions (*e.g.*, myocarditis, pericarditis, and cardiac surgery) activate a rapid pro-inflammatory cascade involving cytokine release, leukocyte infiltration, and myeloperoxidase (MPO) activation, thus leading to atrial structural changes that provide a substrate for the maintenance of AF. Rapid atrial activation is in itself sufficient to generate local and systemic low-grade inflammation, leading to further atrial remodeling and a pro-thrombotic state. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

FKBP12.6 (179). In a murine model, mutations in RyR2 that enhance sarcoplasmic reticulum Ca leak increase susceptibility to AF by rapid atrial pacing, an effect mediated by oxidation-induced dissociation of calstabin2 from RyR2 but independent of calmodulin kinase II (CaMKII) or protein kinase A (142). On the other hand, CaMKII-dependent phosphorylation of RyR2 has been shown to increase diastolic Ca leak in RA myocytes from patients with AF (115). Overall, it is reasonable to speculate that phosphorylation and oxidation act synergistically to increase RYR2 open probability (17, 141). Indeed, oxidative stress can activate CaMKII (45) and phosphorylate RYR2 channels, which then become more prone to oxidation (141). Similarly, experimental evidence suggests that ROS-mediated disturbance of intracellular Ca and Na handling may result in electrical instability and set the stage for the development of AF (162). Importantly, ROS-induced ROS release from mitochondria can prevent ATP production and, consequently, result in activation of sarcolemmal K_{ATP} channels (11). The shorter APD and slower electrical conduction, thus, generated promote re-entry-dependent arrhythmias (5).

Finally, oxidative stress-induced atrial remodeling has been shown to modulate connexin-40 (Cx40) and connexin-43 (Cx43), thereby interfering with gap junctions among atrial cardiomyocytes (37, 156). The ensuing disruption of appropriate cell-to-cell coupling, in turn, affects electrical

conduction and refractoriness, both of which are key determinants of the re-entry circuits that sustain AF (163). The role of connexins in AF is supported by evidence that somatic mutations or polymorphisms in GJA5, the gene coding for Cx40, may predispose to AF by impairing gap-junction assembly or electrical coupling (54, 169). However, the prevalence of rare nonsynonymous sodium nitroprussides polymorphisms in the GJA5 gene in AF patients appears to be low (154), in agreement with the absence of an association between common variants in or near the GJA5 gene and AF in the most recent and largest AF genome-wide association studies (44). There is compelling evidence from both animal (18, 22, 75, 130, 138) and human (42, 72, 114, 167) studies of abnormal Cx40 and Cx43 expression and function in AF (134, 148). Overall, AF seems to be characterized not only by reduced absolute expression of Cx40 and Cx40/Cx43 ratio, but also by enhanced redistribution of both connexins from cell-end gap junctions to lateral margins (41). Heterogeneity and lateralisation either decrease or completely abrogate function of these intercellular ion channels (64, 156), hence decreasing electrical coupling amid cardiomyocytes. Moreover, Cx40 remodeling synergistically co-operates with simultaneously developing fibrosis to increase arrhythmogenicity by promoting anatomically stable re-entries during AF (64). However, the highly discrepant results obtained in different contexts and even within the same animal model obscure the relationship between connexins and AF (41, 73). For instance, higher Cx40 expression was reported in left atrial (LA) samples from patients with lone AF and mitral-valve disease-related AF; however, Cx43 expression increased only in the latter group, suggesting differential trends in connexin expression depending on the underlying pathology (167). The conflicting results provided by Cx40 knockout mice regarding AF vulnerability fuel the ongoing controversy (15, 57). Similarly, small molecules aimed at restoring adequate gap-junction conductance appear to be beneficial in some models (ischemia and mitral-valve disease-related AF) but not in other clinically relevant scenarios (*e.g.*, congestive HF) (56, 145). Noteworthy, gene transfer with either Cx40 or Cx43 has emerged as a promising novel approach to control connexin

expression. Indeed, adenoviral-mediated enhanced Cx43 expression attenuates impaired electrical conduction and decreases AF inducibility (18, 66). Regarding the mechanisms underlying gap-junction remodeling in AF, TNF- α infusion in mice proved to be sufficient to induce sustained atrial fibrosis and decrease Cx40 expression, thus suggesting that down-regulation of gap junctions might contribute to the inflammation-induced increase in AF susceptibility (90).

Possible mechanisms by which oxidative stress and inflammation contribute to the formation of the electrical and structural substrate for AF are summarized in Figure 5.

What Is the Role of Myocardial Endogenous Oxidase Systems in AF?

Direct myocardial generation of ROS appears to play a crucial role in initiating and sustaining AF in animal models and humans (26, 112). Among the several potential sources of ROS present in the atrial myocardium, NADPH oxidases or NOXs, mitochondria, xanthine oxidase (XO), and “uncoupled” NOS have been associated with both the new onset of AF and the AF-induced atrial remodeling (9, 40, 76, 77, 131).

NOXs are multi-subunit transmembrane enzymes that utilize NADPH as an electron donor to reduce oxygen to superoxide anion and hydrogen peroxide. NOX2 was initially discovered in phagocytes several decades ago (83) and since then, six more family members have been identified (176). NOX-dependent ROS production depends on the expression level and the activity of the enzyme. The mode of activation differs among NOX enzymes, but NOX-dependent ROS production in cardiovascular pathology usually involves stimulation by Rac1 and protein kinase C (20). Besides playing a critical role in the microbicidal activity of neutrophils, NOX2 in the myocardium has been involved in the pathogenesis of AF. For example, induction of AF by rapid atrial pacing in pigs was associated with increased NOX-dependent ROS production in the LA (40). AF develops spontaneously in mice with cardiac-specific overexpression of a constitutively active Rac1, which activates NOX2 (3). Kim *et al.* showed that NOX2 was the main source of ROS in human RA myocytes and that

FIG. 5. A diagram depicting possible mechanisms by which oxidative stress and inflammation contribute to the formation of the electrical and structural substrate for AF. Some of the described targets of statin therapy (S) are shown in red. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

FIG. 6. After 2 weeks of AF (2W-AF), NOX2 protein expression and NADPH-stimulated superoxide production were increased in the goat left atria (LA) (A, B) compared with SR. *Ex vivo* incubation with atorvastatin caused a mevalonate-reversible inhibition of Rac1 activity (C, D) and of NADPH-stimulated superoxide production (E) in patients who went on to develop AF after cardiac surgery. RLU, Relative Light Units; postop AF, postoperative AF; RA, right atria; SR, sinus rhythm. Modified from Reilly *et al.* (131). * $P < 0.05$ vs. SR, 1-way ANOVA ($n = 10$ to 19); # $P < 0.05$ for the mevalonate-reversible effect of atorvastatin; 1-way ANOVA ($n = 8$ to 19).

NOX-derived ROS production was increased in RA samples from patients with (mostly paroxysmal) AF (76). Furthermore, atrial NOX2-dependent superoxide production is independently associated with an increased risk of postoperative AF and other in-hospital complications in patients undergoing cardiac surgery (9, 77). More recently, Reilly *et al.* (131) reported an increase in atrial Rac1 and NOX2 protein level and activity 2 weeks after induction of AF in goats and in cardiac surgery patients who go on to develop postoperative AF (Fig. 6). On the other hand, "uncoupled" NOS activity and mitochondrial oxidases become the most important sources of ROS in the setting of longstanding AF and atrial structural remodeling (131). In keeping with these findings, oxidative stress assessed by NOX2 activity and urinary isoprostanes (which result from the interaction of arachidonic acid with ROS) was found to be increased in patients with paroxysmal and recent AF. By contrast, patients with longstanding AF showed similar values of urinary isoprostanes and a modest increase in NOX2 activity compared with controls (25). NOX2 expression in leucocytes is several orders of magnitude higher than that of other cells (16), rendering urinary NOX2 activity a likely marker of neutrophil activation.

Xanthine oxidoreductase has emerged as a relevant source of ROS in cardiovascular diseases and, in particular, in AF. Under physiological conditions, the enzyme functions as a dehydrogenase with NAD^+ as an electron acceptor. After oxidation of critical cysteines or partial cleavage of the enzyme, xanthine oxidoreductase switches to XO and facilitates one- as well as two-electron transfer onto oxygen (117). Thus, in situations of pre-existing oxidative stress or inflammation, XO catalyzes the conversion of hypoxanthine to xanthine and of xanthine to uric acid, and simultaneously produces superoxide anions as well as hydrogen peroxide (52). In addition to increasing oxidative stress, by producing uric acid, XO promotes inflammation through activation of pro-inflammatory cytokines and stimulation of the renin-angiotensin system (166). In keeping with the mechanism of redox-induced conversion from the dehydrogenase to the oxidase form, XO-

dependent endothelial superoxide production is promoted by angiotensin II and the resulting activation of NOX2 (84). Notwithstanding the controversy concerning the role and localization of XO in the heart of nonrodent mammalian species (126), XO has been found in capillary endothelial cells, vascular smooth muscle cells, macrophages, and mast cells (61). Interestingly, the mRNA level of XO in the heart and the vascular system is low, whereas the liver expresses a high level of XO, particularly in the presence of inflammation. As XO binds to the endothelial glycocalyx after secretion into the blood, it is possible that a significant proportion of cardiac XO might originate in the liver and reside in the extracellular rather than the intracellular compartment (168). With regard to AF, XO seems to play different roles in different species. In a porcine model, atrial tachypacing caused a significant increase in XO-dependent superoxide production in the left atrium (40). However, these findings failed to be replicated in RA appendages of patients with AF (76). In a canine model of atrial tachypacing, inhibition of XO with allopurinol abrogated atrial fibrosis and the reduction in endothelial NOS (eNOS), without affecting LA diameter (135). Besides preventing atrial structural remodeling, allopurinol attenuated the electrical remodeling induced by atrial tachypacing (135). In line with these experimental findings, a small cross-sectional study showed a correlation between uric acid levels and LA diameter ($p < 0.001$), a conventional but rather questionable marker of atrial structural remodeling (87). Indeed, uric acid appeared to be an independent predictor of permanent but not paroxysmal AF (adjusted odds ratio [OR] = 0.34, 95% CI: 0.137–0.949, $p = 0.039$) (87), thus reinforcing its potential association with atrial structural remodeling. Moreover, an increasing body of epidemiological data has identified uric acid as a marker of AF risk (79). This association was further supported by the Atherosclerosis Risk In Communities study in which elevated serum uric acid was associated with greater AF risk (adjusted hazard ratio [HR] = 1.16, 95% CI: 1.06–1.26 per SD increase of serum uric acid differences), particularly in women and blacks (153). This gender difference was confirmed in a Japanese cohort study (152), but the mechanisms

underlying it as well as the role of ethnicity remain elusive. Finally, uric acid has also been shown to predict AF recurrence after electrical cardioversion (88). However, whether uric acid is directly involved in the pathogenesis of AF is far from being settled (166), as uric acid is influenced by diet and renal function, two factors that also impact cardiac disease development. Finally, given the dual function of xanthine oxidoreductase, whether the uric acid level is a surrogate for increase XO-mediated oxidative stress remains to be established.

NOS catalyze the generation of NO through the conversion of L-arginine into L-citrulline in the presence of oxygen and several cofactors, such as tetrahydrobiopterin (BH4), flavin cofactors (flavin mononucleotide, flavin adenine dinucleotide), and NADPH. There are three NOS isoforms: NOS1 or neuronal NOS (nNOS); NOS2 or inducible NOS (iNOS); and NOS3 or endothelial NOS (eNOS), two of which (nNOS and eNOS) are constitutively expressed in the cardiovascular system (27). Under physiological conditions, NO generated by NOSs in a tightly regulated manner participates in several cellular signaling pathways. In disease states, increased oxidative stress can lead to an increase in arginase activity, BH4 oxidation (131), and/or S-glutathionylation of the NOS reductase domain (29), all of which can “uncouple” the enzyme’s activity, leading to the production of superoxide rather than NO (48). The reaction of the remaining NO with superoxide (to form highly reactive nitroso-oxidant species such as ONOO⁻) further reduces NO availability.

Pacing-induced short-term AF has been associated with a 46% reduction in LA endocardial eNOS and a significant decrease in NO production (by 73%) (23), whereas longstanding AF in goats or humans is associated with NOS uncoupling secondary to a reduction in atrial BH4 content and an increase in arginase activity (131). It should be noted that atrial mitochondrial and NOS-mediated ROS production in goats was observed both in long-term AF and in the presence of sinus rhythm and atrial remodeling due to atrioventricular block, suggesting that structural atrial remodeling (rather than AF in itself) was responsible for these findings (131).

Others have reported induction of inducible NOS (iNOS) and increased 3-nitrotyrosine (a OONO⁻ biomarker) in RA samples from patients with permanent AF (59) with little or no difference in eNOS expression (26, 59). In addition, the plasma level of the endogenous NOS inhibitor, ADMA, has been shown to be elevated in animals and individuals with persistent AF and to decrease after cardioversion (53). In

failing canine hearts, atrial iNOS uncoupling due to BH4 depletion increased myocardial oxidative stress and was associated with shortening of the atrial effective refractory period and development of a substrate for inducible AF (116). BH4 and L-arginine supplementation restored normal iNOS activity and BH4 level and decreased AF inducibility, implying a potentially important role for NOS-generated ROS in the development of an AF substrate in HF.

Do Anti-Inflammatory and Antioxidant Agents Prevent AF?

Interventional trials of anti-inflammatory agents support a causal link between inflammation and postoperative AF. In a canine model of sterile pericarditis, topical application of the anti-inflammatory drugs ibuprofen and methylprednisolone significantly reduced the incidence of AF (155). In another canine model of atrial tachypacing, administration of prednisone was associated with attenuation of atrial electrical remodeling (resulting in lower AF inducibility), whereas ibuprofen or cyclosporin-A had no effect (144). In keeping with these findings, a double-blind randomized trial of hydrocortisone (100 mg a day for 4 days, starting on the evening before surgery) in 241 consecutive patients with sinus rhythm, undergoing on-pump cardiac surgery (coronary revascularization and/or aortic valve replacement), showed a significant reduction in the new onset AF during the first 84 h after surgery (58) (Fig. 7). This finding is in keeping with that of a meta-analysis of controlled trials (including 621 patients), which shows an average risk reduction of postoperative AF with steroid treatment (at various doses, preparation and duration) of 33% (risk ratio=0.67, 95% CI: 0.54, 0.85, $p=0.001$) (58). Besides preventing new-onset AF, steroids have also been shown to reduce AF recurrence early after radiofrequency ablation (80) (Fig. 7).

Ascorbate supplementation has also been shown to attenuate the pacing-induced atrial electrical remodeling in dogs and the incidence of postoperative AF or atrial flutter (16.3% vs. 34.9% in the ascorbate and control group, respectively) in a nonrandomized, nonplacebo-controlled comparison in 43 patients undergoing cardiac surgery; however, these preliminary findings are still awaiting confirmation in larger controlled trials. A more recent study reported no effect of ascorbate and vitamin E supplementation on AF inducibility in paced dogs, whereas simvastatin prevents both electrical remodeling and AF inducibility in the same model (146).

FIG. 7. Kaplan-Meier curve showing the effect of corticosteroid treatment on the incidence of AF after cardiac surgery (A) or recurrence of AF after pulmonary vein isolation (B). Reprinted with permission from Halonen *et al.* (58) (A) and modified from Koyama *et al.* (80) (B). To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

How do statins reduce inflammation?

Statins inhibit the 3-Hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme of the mevalonate pathway. Mevalonate is required for both cholesterol biosynthesis and the generation of isoprenoids that are involved in the activation of small guanosine triphosphate (GTP)ase signaling molecules. Several large clinical trials have provided evidence supporting the use of statins for the primary and secondary prevention of ischemic heart disease and stroke because of their low density lipoprotein (LDL)-cholesterol-lowering effect (14, 111). In addition, statins have anti-inflammatory and antioxidant properties that are both dependent and independent of cholesterol lowering (122, 128, 175) but which are not independently associated with the beneficial effects on patients' outcome.

The statin-mediated attenuation of isoprenylation reduces the tethering of small GTPases to the plasma membrane already at clinical relevant concentrations (33). This prevents the interaction of guanine nucleotide exchange factors with the GTPase and, thus, attenuates signaling by growth factor and cytokine receptors, as well as integrins, resulting in a global anti-inflammatory effect (177). Moreover, small GTPases of the Rho family, such as RhoA, Rac1, and CDC42, control the cytoskeleton by locally regulating actin polymerization, which impacts mRNA stability, cellular vesicle trafficking, and stress signaling. This aspect might explain why statins in endothelial cells activate a similar signaling cascade as shear stress. For example, similar to laminar flow, statins induce the transcription factor, Kruppel-like factor 2 (KLF2) in endothelial cells, which is an important mediator of cellular quiescence (12). KLF2, in turn, regulates the expression of multiple target genes, thus promoting an anti-inflammatory and anti-thrombotic endothelial phenotype (12). Several mechanisms have been proposed to mediate the up-regulation of KLF2 by statins, such as activation of the Ras homolog pathway, inhibition of mammalian target of rapamycin complex 1 (MTORC1) (147). MTORC1 activation requires Ras homolog enriched in brain (Rheb), an isoprenylated GTPase of the Ras family, and statin inhibition of Rheb was shown to prevent MTORC1 activation in vascular smooth muscle cells (161). In agreement with this, statin effects were abrogated by geranylgeranyl pyrophosphate but not farnesyl pyrophosphate, thereby implicating inhibition of geranylgeranyl pyrophosphate synthesis, and thus the Ras homolog pathway, in KLF2 induction. Inhibition of protein isoprenylation by statins has been found to influence the JAK/Signal transducer and activator of transcription signaling pathway, an intracellular signalling pathway that is activated by inflammatory cytokines in the endothelium (69). Furthermore, growth factor signaling, as activated by angiotensin II, thrombin, endothelial growth factor, platelet-derived growth factor, and the pro-fibrotic transforming growth factor β , is also attenuated by statin treatment (177). More recently, two alternative pathways have been implicated in the interaction between statins and KLF2. Lee *et al.* demonstrated that statins reverted hyperglycemia-induced overexpression of FOXO1, both *in vitro* and in a mice model of type 2 diabetes mellitus, and thus relieved the negative effect of FOXO1 on KLF2 expression (86). McLean *et al.* (108) showed that apelin/apelin receptor (APJ) signaling mediated statin-induced up-regulation of KLF2, eNOS, and thrombomodulin and the KLF2

increased expression of APJ, in a positive feedback loop. However, further studies are warranted to determine whether statins directly activate APJ or potentiate apelin-mediated activation of APJ (108).

Besides the aforementioned direct effects on the endothelium, statins can also act indirectly, for instance, by reducing T-cell cytotoxic activity against endothelial cells (136). On the other hand, statins can exert a strong anti-inflammatory and anti-thrombotic effect on blood monocyte-macrophages by decreasing the expression of many pro-inflammatory cytokines and coagulation factors. Those effects depend on modulation of several transcription factors, such as induction of peroxisome proliferator-activated factor (PPAR)- α , PPAR- γ , and KLF2 and inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells and c-ets (172).

KLF4, another member of the Kruppel-like family, has also been identified as a key regulator of endothelial homeostasis (143). Akin to KLF2, it seems to mediate the anti-inflammatory actions of statins in both endothelial cells and macrophages through the MEK5/mitogen-activated protein kinase pathway (118, 158), but its precise functions as well as the putative interaction with KLF2 remain poorly understood.

Finally, statins can activate the phospholipase A(2)-cyclooxygenase pathway, shifting the balance toward increased synthesis of the vasodilator and anti-inflammatory prostacyclin instead of other vasoconstrictor and thrombogenic prostaglandins (170).

How do statins reduce oxidative stress?

Oxidative stress can induce inflammation and senescence in endothelial cells, and statins can prevent those effects and thus improve endothelial function (120, 177). Indeed, various intracellular signaling pathways have been proposed to underlie statin-enhanced expression and activity of NOS3, sir-tuin 1, and catalase. The best characterized are activation of PI3K/Akt and AMP-activated protein kinase signaling (51, 82, 151), inhibition of geranylgeranylation of the small G-protein Rho and its downstream target Rho-associated protein kinase (85), and suppression of caveolin-1 (124). In addition, statins improve eNOS function by increasing intracellular BH4 bioavailability and, possibly, by reducing ADMA levels (101) and arginase expression (63). An increase in NO bioavailability would then be expected to inhibit overexpression of adhesion molecules involved in leukocyte-endothelial cell interaction, and preserve mitochondrial membrane potential in response to oxidative stress in cardiac myocytes (68, 105). Furthermore, statins improve differentiation, survival, and functional activity of endothelial progenitor cells, which are disturbed by oxidative stress and inflammatory stimuli (97). In this way, they may contribute to angiogenesis and re-endothelialization of injured vessels (47, 164). Statins can also prevent oxidative stress by inhibiting NOX2 activity. Indeed, in addition to inhibiting transcription of NOX2 subunits, statins inhibit geranylgeranylation and thus membrane translocation of Rac1 GTPase (141, 160), which is required for activation of NOX2 (165) (Fig. 6). *Ex vivo*, atorvastatin has been shown to prevent the angiotensin-II-mediated increase in L-type Ca channels (LTCC) and Ca transient amplitude in HL-1 cells by inhibiting protein kinase C and NOX2 activity (171); however, the significance of these findings in the pathogenesis of AF (which is characterized by a reduction in

atrial LTCC and sarcolemmal Ca current) remains to be addressed.

It should be noted that the anti-inflammatory and antioxidant pleiotropic effects of statins in animal models have generally been observed with doses/concentration of statins that are higher than those employed in the clinical setting, thereby casting some doubt on their relevance to patients on statin therapy.⁽¹⁹⁾ However, in keeping with previous results obtained *in vitro* and in mice models, a randomized, double-blind, placebo controlled study in patients undergoing cardiac surgery showed that 3-day treatment with atorvastatin 40 mg once daily (od) before surgery attenuated oxidative stress by inhibiting vascular and atrial Rac1-mediated activation of NOX2 (8, 9) (Fig. 1). Of note, these effects occurred before an LDL cholesterol reduction could be detected, and they were reproduced by incubation with atorvastatin *ex vivo* and reversed by mevalonate (8, 9, 131).

The putative effects of statins on oxidative stress and inflammation in AF are schematically summarized in Figure 5.

What is the Role of Statins in the Management of AF?

A number of observational studies and small clinical trials have assessed the efficacy of statins in a variety of settings and populations; however, the results are far from being consensual and there is still controversy regarding the role of statins in the primary and secondary prevention of AF.

Primary prevention of AF

Data from the nationwide French Registry of Acute ST Elevation or Non-ST Elevation Myocardial Infarction register, an observational study of patients hospitalized for acute myocardial infarction, provided the first link between statin therapy and a reduction in acute AF risk (OR=0.64, 95% CI: 0.45–0.92, $p=0.017$). Furthermore, results suggested a dose-response relationship, with intensive statin therapy achieving greater risk reduction than conventional therapy (36). The protective effect of statins on incident AF was further supported by a large epidemiological study (involving 27,002 subjects older than 65 years from the Taiwanese National Health Insurance research database followed up for 9 years) (65), in which the highest risk reduction associated with statin treatment was found in patients with a CHADS2 score ≥ 2 (adjusted HR=0.69, 95% CI: 0.57–0.85, $p<0.001$). Even though patients on statins had more cardiovascular comorbidities than controls, statin therapy remained a protective factor against new-onset AF after adjusting for potential confounders (adjusted HR=0.81, 95% CI: 0.69–0.95, $p=0.009$). However, a recent meta-analysis (nine randomized controlled trials with almost 60,000 patients) refuted this association and reported similar AF incidence regardless of statin treatment (OR=1.00, 95% CI: 0.86–1.15, $p=0.95$) (46). The protective role of statins in AF prevention in patients with coronary artery disease remains a matter of heated debate (2, 81, 125, 174). Indeed, in the Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial, the protection afforded by statin treatment in patients with acute coronary disease did not reach statistical significance (OR=0.97, 95% CI: 0.72–1.31) (78). More recently, a meta-analysis suggested that statins could reduce the AF risk in patients with acute coronary syndrome. Pooled results from six studies, with more than 160,000 patients (four studies with new-onset AF and two with AF in baseline), revealed an overall risk reduction of 35% with statin therapy (95% CI: 0.55–0.77, $p<0.0001$), with

the benefit being more conspicuous for new-onset AF (RR=0.59, 95% CI: 0.48–0.73, $p=0.096$) than for secondary prevention of AF (RR=0.70, 95% CI: 0.43–1.14, $p=0.085$) (178). Finally a meta-analysis including all large-scale statin trials did not show a significant reduction in atrial fibrillation in the active treatment group (RR=0.95, 95% CI: 0.88–1.03, $p=0.24$), and seven longer-term trials of more intensive *versus* standard statin regimens also showed no evidence of a reduction in the risk of atrial fibrillation (RR=1.00, 95% CI: 0.90–1.12, $p=0.99$) (129). Taken together, these findings suggest that statin treatment is not effective in the primary prevention of AF; however, it should be noted that AF was either not recorded or not included among the outcomes of the largest statin trials and event information for these analyses was mostly based on routinely collected data on adverse events.

AF recurrence after cardioversion or radiofrequency ablation

Taking into account the relatively high rate of AF recurrence after catheter ablation and the postprocedural inflammatory state, 125 patients undergoing catheter ablation of AF were randomized in a prospective, double-blind, placebo-controlled trial to receive 80 mg atorvastatin or placebo for 3 months (150). There was no difference in symptomatic AF between groups (5% in atorvastatin *vs.* 6.5% in placebo, $p=0.75$) or in the recurrence of atrial arrhythmia after ablation (15% in atorvastatin *vs.* 12% in placebo, $p=0.37$). Failure to suppress arrhythmia occurred despite a significant decrease in LDL-cholesterol and mean CRP levels (mean change -0.75 ± 3 , $p=0.02$) with statins, pointing to a reduction in systemic inflammation (150).

Electrical cardioversion remains the most commonly used method for sinus rhythm restoration in patients with persistent AF, albeit with a fairly modest rate of success even in conjunction with new antiarrhythmic drugs (137). Contrary to the absence of benefit on AF recurrence after ablation, there is a trend toward a protective role of statins against arrhythmia after successful cardioversion. In a meta-analysis of six studies (515 patients with persistent AF), upstream statin therapy achieved a significant reduction in AF relapse after successful electrical cardioversion (OR=0.662, 95% CI: 0.45–0.96, $p=0.03$) (99). Even though the results of this meta-analysis are of potential interest, the studies included were small, of low quality, and very heterogeneous concerning type and dosage of statin. Therefore, more than changing clinical practice, these findings provide a useful background for planning future larger studies. Taken together, these findings are in line with a previous meta-analysis that compared efficacy of statins for secondary prevention of AF, either after electrical cardioversion or after ablation, which showed that statin treatment had no effect on AF recurrence after ablation (four studies, including 750 patients; RR=1.04, 95% CI: 0.85–1.28, $p=0.71$) but appeared to reduce the risk of AF relapse after cardioversion (12 studies, including 1790 patients; RR=0.78, 95% CI: 0.67–0.90, $p=0.0003$). Nonetheless, the latter result was no longer significant when the analysis was restricted to randomized controlled trials (five studies, 458 patients, RR=0.76, 95% CI: 0.48–1.20) (38). In summary, there is no indication for statin therapy solely on the basis of prevention of AF recurrence.

AF in HF

AF is a common comorbidity in patients with HF and each adversely affects the other, as their co-existence is associated

with worse long-term prognosis (109). Despite the apparent benefit of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in reducing AF in patients with HF (102, 104, 157), the role of statins for AF prophylaxis in HF is far from being completely understood (103). The double-blind, placebo-controlled trial GISSI-HF found that rosuvastatin marginally reduced the incidence of AF in 3690 patients with HF (13.9% on rosuvastatin *vs.* 16.0% on placebo), even though the difference only reached statistical significance after adjustment for clinical variables, laboratory examinations, and background therapies ($p=0.038$) (103). This study raises the possibility that statins may prevent the development of AF in patients with HF, but larger studies, considering AF as primary endpoint, are warranted to confirm this finding. The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico on heart failure (GISSI-HF) trial confirmed that history of earlier AF enhanced susceptibility to new episodes of AF over the follow up (103), but did not show any difference in the efficacy of rosuvastatin between groups.

Postoperative AF

Postoperative AF is the most common postoperative arrhythmic complication, occurring in approximately 40% of cardiac surgery patients. Since postoperative AF is associated with adverse cardiovascular events (*e.g.*, HF, stroke), prolonged hospitalization and increased overall morbidity and mortality, prevention of its development improves prognosis of patients undergoing cardiac surgery (89).

Numerous observational studies [*e.g.*, (28, 62, 107, 121)] suggest that pre- or perioperative statin treatment reduces the occurrence of AF and improves clinical outcome in patients undergoing cardiac or major vascular surgery (by causing a 50%–70% reduction in perioperative myocardial infarction or mortality). However, in two large cohort studies, statin therapy failed to decrease (159) or even increased (110) incidence of postoperative AF. The first controlled clinical trial attesting the efficacy of perioperative statin treatment in the prevention of postoperative AF was ARMYDA-3 (Atorvastatin for Reduction

of MYocardial Dysrhythmia After cardiac surgery), there was a 61% reduction in AF risk (evaluated by continuous electrocardiogram (ECG) monitoring) in 200 statin naïve patients undergoing elective cardiac surgery but there was no effect on postoperative CRP or cardiac/cerebrovascular events (123). In a recent meta-analysis of 10 randomized trials (of which only four had postoperative AF as a predefined outcome) (46) evaluating the use of perioperative statin treatment in patients undergoing cardiac surgery ($n=1001$ patients in total—study size between 40 and 200 patients), statin use was found to reduce patients' relative risk of developing postoperative AF by 63% (RR=0.37, 95% CI: 0.28–0.51) (Fig. 8). Although these findings would be consistent with a rapid and, possibly, lipid-independent antiarrhythmic effect of statins, they have important limitations (*e.g.*, small size, nonsystematic use of continuous ECG monitoring, mostly "ancillary findings") and are less bearing on current day-to-day clinical practice, as they only randomized patients who were not on statin treatment. A large, placebo-controlled, randomized clinical trial of the effect of rosuvastatin (20 mg od) in patients undergoing cardiac surgery (www.clinicaltrials.gov/ct2/show/NCT01573143?term=STICS&rank=1) will address these pending issues. Noteworthy, the beneficial effects of statins seem to go beyond the prevention of postoperative AF. A meta-analysis of 15 randomized controlled trials (2292 patients undergoing cardiac and noncardiac surgery) showed that statins not only decrease the incidence of postoperative AF but also reduce postoperative myocardial infarction (RR=0.53, 95% CI: 0.38–0.74), in-hospital length of stay (standardized mean difference = -0.32 , 95% CI: -0.53 to -0.11), and mortality (RR=0.62, 95% CI: 0.34–1.14), albeit not meeting the threshold for statistical significance in this case (31).

Together, these findings suggest that aggressive perioperative statin treatment may be a risk-reducing intervention in patients undergoing major surgery.

Conclusions

In conclusion, the clinical impact of the anti-inflammatory and antioxidant effects of statin therapy remains to be

FIG. 8. A meta-analysis of 10 randomized trials (only four of which had postoperative AF as a predefined outcome) suggests that statin therapy might reduce the risk of developing postoperative AF by 63%. CI—confidence interval, OR—odds ratio. Modified from Fauchier *et al.* (46).

demonstrated. As their anti-arrhythmic effects are concerned, statins appear to attain the highest benefit in the prevention of postoperative AF, although this finding needs to be confirmed by larger clinical trials. The efficacy for secondary prevention of AF by statin therapy, albeit lower, might still be significant in some settings but not after ablation. On the other hand, statins seem to have a fairly limited benefit, if any, in the primary prevention of AF. To date, the antiarrhythmic effect of statins does not hitherto support prescribing these agents for the sole purpose of preventing incident AF or its recurrence. Large-scale randomized clinical trials are warranted to shed light on some unsolved issues, particularly regarding the benefit of statins for the management of AF in specific patients' subgroups.

Innovation

Antioxidant and anti-inflammatory effects of statins have been extensively described in animal models and humans; however, their relevance to patients' outcome remains unproven. A scattering of small clinical trials suggests that perioperative statin treatment may prevent the new onset of AF after cardiac surgery. However, the efficacy of statin therapy in AF's secondary prevention might only be significant in some settings; similarly, statins appear to be of little or no benefit in AF's primary prevention. Nevertheless, the available evidence is not robust (single-center studies of small size or "ancillary" finding from studies designed to detect other outcomes), and larger dedicated trials are needed to conclusively test this hypothesis.

Acknowledgments

The authors are grateful for the support of the British Heart Foundation, the Fondation Leducq (Transatlantic Networks of Excellence on redox and nitrosative regulation of cardiac remodeling), and the European Union (FP7 Collaborative project EUTRAF, 261057).

References

- Ad N, Henry L, and Hunt S. The impact of surgical ablation in patients with low ejection fraction, heart failure, and atrial fibrillation. *Eur J Cardiothorac Surg* 40: 70–76, 2011.
- Adabag AS, Nelson DB, and Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. *Am Heart J* 154: 1140–1145, 2007.
- Adam O, Frost G, Custodis F, Sussman MA, Schafers HJ, Bohm M, and Laufs U. Role of Rac1 GTPase activation in atrial fibrillation. *J Am Coll Cardiol* 50: 359–367, 2007.
- Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimbürger M, Aubier M, Mercadier JJ, Reed JC, and Hatem SN. Myocardial cell death in fibrillating and dilated human right atria. *J Am Coll Cardiol* 34: 1577–1586, 1999.
- Akar FG, Aon MA, Tomaselli GF, and O'Rourke B. The mitochondrial origin of postischemic arrhythmias. *J Clin Invest* 115: 3527–3535, 2005.
- Anselmi A, Possati G, and Gaudino M. Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? *Ann Thorac Surg* 88: 326–333, 2009.
- Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, and Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. *J Am Coll Cardiol* 54: 669–677, 2009.
- Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos AS, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, and Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. *Circulation* 122: S66–S73, 2010.
- Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R, Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, Channon KM, and Casadei B. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. *J Am Coll Cardiol* 59: 60–70, 2012.
- Antoniades C, Van-Assche T, Shirodaria C, Diesch J, Antonopoulos AS, Lee J, Cunningham C, Tousoulis D, Stefanadis C, Casadei B, Taggart D, Channon KM, and Leeson P. Preoperative sCD40L levels predict risk of atrial fibrillation after off-pump coronary artery bypass graft surgery. *Circulation* 120: S170–S176, 2009.
- Aon MA, Cortassa S, Marban E, and O'Rourke B. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. *J Biol Chem* 278: 44735–44744, 2003.
- Atkins GB and Jain MK. Role of Kruppel-like transcription factors in endothelial biology. *Circ Res* 100: 1686–1695, 2007.
- Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagener DR, Psaty BM, Lauer MS, and Chung MK. Inflammation as a risk factor for atrial fibrillation. *Circulation* 108: 3006–3010, 2003.
- Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, Peto R, Barnes EH, Keech A, Simes J, and Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 376: 1670–1681, 2010.
- Beauchamp P, Yamada KA, Baertschi AJ, Green K, Kanter EM, Saffitz JE, and Kleber AG. Relative contributions of connexins 40 and 43 to atrial impulse propagation in synthetic strands of neonatal and fetal murine cardiomyocytes. *Circ Res* 99: 1216–1224, 2006.
- Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. *Physiol Rev* 87: 245–313, 2007.
- Belevych AE, Terentyev D, Terentyeva R, Nishijima Y, Sridhar A, Hamlin RL, Carnes CA, and Gyorke S. The relationship between arrhythmogenesis and impaired contractility in heart failure: role of altered ryanodine receptor function. *Cardiovasc Res* 90: 493–502, 2011.
- Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA, and Bauer A. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. *Cardiovasc Res* 92: 218–225, 2011.
- Bjorkhem-Bergman L, Lindh JD, and Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? *Br J Clin Pharmacol* 72: 164–165, 2011.
- Brandes RP and Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. *Cardiovasc Res* 65: 16–27, 2005.

21. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijssman L, Trouwborst A, and Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. *Circulation* 96: 3542–3548, 1997.
22. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, and Nattel S. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. *Circ Res* 105: 1213–1222, 2009.
23. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC, Jr., Harrison DG, and Langberg JJ. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. *Circulation* 106: 2854–2858, 2002.
24. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, and Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. *Europace* 14: 1385–1413, 2012.
25. Cangemi R, Celestini A, Calvieri C, Carnevale R, Pastori D, Nocella C, Vicario T, Pignatelli P, and Violi F. Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. *Heart* 98: 1063–1066, 2012.
26. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, and Van Wagoner DR. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. *Circ Res* 89: E32–E38, 2001.
27. Carnicer R, Crabtree MJ, Sivakumaran V, Casadei B, and Kass DA. Nitric oxide synthases in heart failure. *Antioxid Redox Signal* 18: 1078–1099, 2013.
28. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, and Ellis SG. Relation of inflammation and benefit of statins after percutaneous coronary interventions. *Circulation* 107: 1750–1756, 2003.
29. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, and Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. *Nature* 468: 1115–1118, 2010.
30. Chen YB, Shu J, Yang WT, Shi L, Guo XF, Wang FG, and Qian YY. Meta-analysis of randomized trials comparing the effectiveness of on-pump and off-pump coronary artery bypass. *Chin Med J (Engl)* 125: 338–344, 2012.
31. Chopra V, Wesorick DH, Sussman JB, Greene T, Rogers M, Froehlich JB, Eagle KA, and Saint S. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. *Arch Surg* 147: 181–189, 2012.
32. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, and Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. *Circulation* 104: 2886–2891, 2001.
33. Cicha I, Schneiderhan-Marra N, Yilmaz A, Garlich CD, and Goppelt-Strube M. Monitoring the cellular effects of HMG-CoA reductase inhibitors *in vitro* and *ex vivo*. *Arterioscler Thromb Vasc Biol* 24: 2046–2050, 2004.
34. Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, Cook NR, Buring JE, and Albert CM. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. *Eur Heart J* 31: 1730–1736, 2010.
35. Conway DS, Buggins P, Hughes E, and Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. *J Am Coll Cardiol* 43: 2075–2082, 2004.
36. Danchin N, Fauchier L, Marijon E, Barnay C, Furber A, Mabo P, Bernard P, Blanc JJ, Jouven X, Le Heuzey JY, Charbonnier B, Ferrieres J, and Simon T. Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. *Heart* 96: 1809–1814, 2010.
37. Davis LM, Kanter HL, Beyer EC, and Saffitz JE. Distinct gap junction protein phenotypes in cardiac tissues with disparate conduction properties. *J Am Coll Cardiol* 24: 1124–1132, 1994.
38. Dentali F, Gianni M, Squizzato A, Ageno W, Castiglioni L, Maroni L, Hylek EM, Grandi AM, Cazzani E, Venco A, and Guasti L. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. *Thromb Haemost* 106: 363–370, 2011.
39. Dernellis J and Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. *Eur Heart J* 25: 1100–1107, 2004.
40. Dudley SC, Jr., Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, and Langberg J. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. *Circulation* 112: 1266–1273, 2005.
41. Duffy HS and Wit AL. Is there a role for remodeled connexins in AF? No simple answers. *J Mol Cell Cardiol* 44: 4–13, 2008.
42. Dupont E, Ko Y, Rothery S, Coppen SR, Baghai M, Haw M, and Severs NJ. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. *Circulation* 103: 842–849, 2001.
43. Eager KR and Dulhunty AF. Activation of the cardiac ryanodine receptor by sulphydryl oxidation is modified by Mg²⁺ and ATP. *J Membr Biol* 163: 9–18, 1998.
44. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Muller-Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung MK, Dorr M, Ozaki K, Roberts JD, Smith JG, Pfeufer A, Sinner MF, Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van Wagoner DR, Magnani JW, Wakili R, Clauss S, Rotter JJ, Steinbeck G, Launer LJ, Davies RW, Borkovich M, Harris TB, Lin H, Volker U, Volzke H, Milan DJ, Hofman A, Boerwinkle E, Chen LY, Soliman EZ, Voight BF, Li G, Chakravarti A, Kubo M, Tedrow UB, Rose LM, Ridker PM, Conen D, Tsunoda T, Furukawa T, Sotoodehnia N, Xu S, Kamatani N, Levy D, Nakamura Y, Parvez B, Mahida S, Furie KL, Rosand J, Muhammad R, Psaty BM, Meitinger T, Perz S, Wichmann HE, Wittman JC, Kao WH, Kathiresan S, Roden DM, Uitterlinden AG, Rivadeneira F, McKnight B, Sjogren M, Newman AB, Liu Y, Gollob MH, Melander O, Tanaka T, Stricker BH, Felix SB, Alonso A, Darbar D, Barnard J, Chasman DI, Heckbert SR, Benjamin EJ, Gudnason V, and Kaab S. Meta-analysis identifies six new

- susceptibility loci for atrial fibrillation. *Nat Genet* 44: 670–675, 2012.
45. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJ, Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ, and Anderson ME. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. *Cell* 133: 462–474, 2008.
 46. Fauchier L, Clementy N, and Babuty D. Statin therapy and atrial fibrillation: systematic review and updated meta-analysis of published randomized controlled trials. *Curr Opin Cardiol* 28: 7–18, 2013.
 47. Fleissner F and Thum T. Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. *Antioxid Redox Signal* 15: 933–948, 2011.
 48. Forstermann U and Sessa WC. Nitric oxide synthases: regulation and function. *Eur Heart J* 33: 829–837, 837a–837d, 2012.
 49. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. *Circulation* 96: 1180–1184, 1997.
 50. Fukahara K, Kotoh K, Doi T, Misaki T, and Sumi S. Impact of preoperative atrial fibrillation on the late outcome of off-pump coronary artery bypass surgery. *Eur J Cardiothorac Surg* 38: 366–372, 2010.
 51. Ghaffari N, Ball C, Kennedy JA, Stafford I, and Beltrame JF. Acute modulation of vasoconstrictor responses by pravastatin in small vessels. *Circ J* 75: 1506–1514, 2011.
 52. Glantzounis GK, Tsimoyiannis EC, Kappas AM, and Galaris DA. Uric acid and oxidative stress. *Curr Pharm Des* 11: 4145–4151, 2005.
 53. Goette A, Hammwöhner M, Bukowska A, Scalera F, Martens-Lobenhoffer J, Dobrev D, Ravens U, Weinert S, Medunjanin S, Lendeckel U, and Bode-Boger SM. The impact of rapid atrial pacing on ADMA and endothelial NOS. *Int J Cardiol* 154: 141–146, 2012.
 54. Gollob MH, Jones DL, Krahm AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, Tesson F, Klein GJ, Yee R, Skanes AC, Guiraudon GM, Ebihara L, and Bai D. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. *N Engl J Med* 354: 2677–2688, 2006.
 55. Greiser M, Lederer WJ, and Schotten U. Alterations of atrial Ca(2+) handling as cause and consequence of atrial fibrillation. *Cardiovasc Res* 89: 722–733, 2011.
 56. Guerra JM, Everett TH 4th, Lee KW, Wilson E, and Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. *Circulation* 114: 110–118, 2006.
 57. Hagedorff A, Schumacher B, Kirchhoff S, Luderitz B, and Willecke K. Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. *Circulation* 99: 1508–1515, 1999.
 58. Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M, Hippelainen M, Juvonen T, Hartikainen J, and Hakala T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. *JAMA* 297: 1562–1567, 2007.
 59. Han W, Fu S, Wei N, Xie B, Li W, Yang S, Li Y, Liang Z, and Huo H. Nitric oxide overproduction derived from inducible nitric oxide synthase increases cardiomyocyte apoptosis in human atrial fibrillation. *Int J Cardiol* 130: 165–173, 2008.
 60. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, and Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart J* 27: 949–953, 2006.
 61. Hellsten-Westling Y. Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle. *Histochemistry* 100: 215–222, 1993.
 62. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, Haude M, Heusch G, and Erbel R. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. *Circulation* 106: 2180–2183, 2002.
 63. Holowatz LA, Santhanam L, Webb A, Berkowitz DE, and Kenney WL. Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans. *J Physiol* 589: 2093–2103, 2011.
 64. Hsieh MH, Lin YJ, Wang HH, Lo LW, Chang SL, Yan YL, Chou TY, Chen SA, and Yeh HI. Functional characterization of atrial electrograms in a pacing-induced heart failure model of atrial fibrillation: importance of regional atrial connexin40 remodeling. *J Cardiovasc Electrophysiol* 24: 573–582, 2013.
 65. Hung CY, Lin CH, Loh el-W, Ting CT, and Wu TJ. CHADS(2) score, statin therapy, and risks of atrial fibrillation. *Am J Med* 126: 133–140, 2013.
 66. Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS, and Donahue JK. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. *Circulation* 125: 216–225, 2012.
 67. Ishii Y, Schuessler RB, Gaynor SL, Yamada K, Fu AS, Boineau JP, and Damiano RJ, Jr. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. *Circulation* 111: 2881–2888, 2005.
 68. Jones SP, Teshima Y, Akao M, and Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. *Circ Res* 93: 697–699, 2003.
 69. Jougasaki M, Ichiki T, Takenoshita Y, and Setoguchi M. Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. *Br J Pharmacol* 159: 1294–1303, 2010.
 70. Kaireviciute D, Aidietis A, and Lip GY. Atrial fibrillation following cardiac surgery: clinical features and preventative strategies. *Eur Heart J* 30: 410–425, 2009.
 71. Kallergis EM, Manios EG, Kanoupakis EM, Mavrikakis HE, Kolyvaki SG, Lyrarakis GM, Chlouverakis GI, and Vardas PE. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. *Heart* 94: 200–204, 2008.
 72. Kanagaratnam P, Cherian A, Stanbridge RD, Glenville B, Severs NJ, and Peters NS. Relationship between connexins and atrial activation during human atrial fibrillation. *J Cardiovasc Electrophysiol* 15: 206–216, 2004.
 73. Kato T, Iwasaki YK, and Nattel S. Connexins and atrial fibrillation: filling in the gaps. *Circulation* 125: 203–206, 2012.
 74. Kim MH. Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation. *Expert Rev Clin Pharmacol* 5: 163–171, 2012.

75. Kim SJ, Choisy SC, Barman P, Zhang H, Hancox JC, Jones SA, and James AF. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. *Circ Arrhythm Electrophysiol* 4: 761–769, 2011.
76. Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, and Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. *Circ Res* 97: 629–636, 2005.
77. Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, and Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. *J Am Coll Cardiol* 51: 68–74, 2008.
78. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, and Ganz P. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. *Arterioscler Thromb Vasc Biol* 28: 142–147, 2008.
79. Korantzopoulos P, Letsas KP, and Liu T. Xanthine oxidase and uric acid in atrial fibrillation. *Front Physiol* 3: 150, 2012.
80. Koyama T, Tada H, Sekiguchi Y, Arimoto T, Yamasaki H, Kuroki K, Machino T, Tajiri K, Zhu XD, Kanemoto-Igarashi M, Sugiyasu A, Kuga K, Nakata Y, and Aonuma K. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. *J Am Coll Cardiol* 56: 1463–1472, 2010.
81. Kulik A, Singh JP, Levin R, Avorn J, and Choudhry NK. Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. *Am J Cardiol* 105: 1655–1660, 2010.
82. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. *Nat Med* 6: 1004–1010, 2000.
83. Lambeth JD. NOX enzymes and the biology of reactive oxygen. *Nat Rev Immunol* 4: 181–189, 2004.
84. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, and Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. *Arterioscler Thromb Vasc Biol* 27: 943–948, 2007.
85. Laufs U and Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. *J Biol Chem* 273: 24266–24271, 1998.
86. Lee HY, Youn SW, Cho HJ, Kwon YW, Lee SW, Kim SJ, Park YB, Oh BH, and Kim HS. FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kruppel-like factor 2. *Cardiovasc Res* 97: 143–152, 2012.
87. Letsas KP, Korantzopoulos P, Filippatos GS, Mihas CC, Markou V, Gavrielatos G, Efremidis M, Sideris A, and Kardaras F. Uric acid elevation in atrial fibrillation. *Hellenic J Cardiol* 51: 209–213, 2010.
88. Letsas KP, Siklody CH, Korantzopoulos P, Weber R, Burkle G, Mihas CC, Kalusche D, and Arentz T. The impact of body mass index on the efficacy and safety of catheter ablation of atrial fibrillation. *Int J Cardiol* 164: 94–98, 2013.
89. Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, and Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. *Cochrane Database Syst Rev* 4: CD008493, 2012.
90. Liew R, Khairunnisa K, Gu Y, Tee N, Yin NO, Naylynn TM, and Moe KT. Role of tumor necrosis factor- α in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. *Circ J* 77: 1171–1179, 2013.
91. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH, Leong DP, Brooks AG, Young GD, Kistler PM, Kalman JM, Worthley MI, and Sanders P. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. *J Am Coll Cardiol* 61: 852–860, 2013.
92. Lip GY and Tse HF. Management of atrial fibrillation. *Lancet* 370: 604–618, 2007.
93. Liu G, Abramson JJ, Zable AC, and Pessah IN. Direct evidence for the existence and functional role of hyperreactive sulfhydryls on the ryanodine receptor-triadin complex selectively labeled by the coumarin maleimide 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin. *Mol Pharmacol* 45: 189–200, 1994.
94. Liu T, Li G, Li L, and Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. *J Am Coll Cardiol* 49: 1642–1648, 2007.
95. Liu T, Li L, Korantzopoulos P, Goudevenos JA, and Li G. Meta-analysis of association between C-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation. *Am J Cardiol* 101: 1749–1752, 2008.
96. Liuba I, Ahlroth H, Jonasson L, Englund A, Jonsson A, Safstrom K, and Walfridsson H. Source of inflammatory markers in patients with atrial fibrillation. *Europace* 10: 848–853, 2008.
97. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, and Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. *J Clin Invest* 108: 399–405, 2001.
98. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, and Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation* 110: 1042–1046, 2004.
99. Loffredo L, Angelico F, Perri L, and Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. *BMC Cardiovasc Disord* 12: 107, 2012.
100. Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C, Palamara A, and Santini M. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. *Am J Cardiol* 99: 1421–1424, 2007.
101. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, and Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. *Am J Cardiol* 94: 157–161, 2004.
102. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, and Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. *Circulation* 106: 331–336, 2002.
103. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, Tognoni G, and Tavazzi L. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. *Eur Heart J* 30: 2327–2336, 2009.
104. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, and Cohn JN.

- Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J* 149: 548–557, 2005.
105. Mangialardi G, Monopoli A, Ongini E, Spinetti G, Fortunato O, Emanuelli C, and Madeddu P. Nitric oxide-donating statin improves multiple functions of circulating angiogenic cells. *Br J Pharmacol* 164: 570–583, 2011.
 106. Marengo JJ, Hidalgo C, and Bull R. Sulfhydryl oxidation modifies the calcium dependence of ryanodine-sensitive calcium channels of excitable cells. *Biophys J* 74: 1263–1277, 1998.
 107. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, Oliver C, Gomez-Plana J, Lip GY, and Valdes M. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. *Am J Cardiol* 97: 55–60, 2006.
 108. McLean DL, Kim J, Kang Y, Shi H, Atkins GB, Jain MK, and Chun HJ. Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells—brief report. *Arterioscler Thromb Vasc Biol* 32: 2640–2643, 2012.
 109. McManus DD, Saczynski JS, Lessard D, Kinno M, Pidikiti R, Esa N, Harrington J, and Goldberg RJ. Recent trends in the incidence, treatment, and prognosis of patients with heart failure and atrial fibrillation (the Worcester Heart Failure Study). *Am J Cardiol* 111: 1460–1465, 2013.
 110. Miceli A, Fino C, Fiorani B, Yeatman M, Narayan P, Angelini GD, and Caputo M. Effects of preoperative statin treatment on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. *Ann Thorac Surg* 87: 1853–1858, 2009.
 111. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, and Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 380: 581–590, 2012.
 112. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, and Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. *Circulation* 104: 174–180, 2001.
 113. Morgera T, Di Lenarda A, Dreas L, Pinamonti B, Humar F, Bussani R, Silvestri F, Chersevani D, and Camerini F. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. *Am Heart J* 124: 455–467, 1992.
 114. Nao T, Ohkusa T, Hisamatsu Y, Inoue N, Matsumoto T, Yamada J, Shimizu A, Yoshiga Y, Yamagata T, Kobayashi S, Yano M, Hamano K, and Matsuzaki M. Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm. *Am J Cardiol* 91: 678–683, 2003.
 115. Neef S, Dybkova N, Sossalla S, Ort KR, Fluschnik N, Neumann K, Seipelt R, Schondube FA, Hasenfuss G, and Maier LS. CaMKII-dependent diastolic SR Ca²⁺ leak and elevated diastolic Ca²⁺ levels in right atrial myocardium of patients with atrial fibrillation. *Circ Res* 106: 1134–1144, 2010.
 116. Nishijima Y, Sridhar A, Bonilla I, Velayutham M, Khan M, Terentyeva R, Li C, Kuppusamy P, Elton TS, Terentyev D, Gyorke S, Zweier JL, Cardounel AJ, and Carnes CA. Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology. *Cardiovasc Res* 91: 71–79, 2011.
 117. Nishino T, Okamoto K, Eger BT, and Pai EF. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. *FEBS J* 275: 3278–3289, 2008.
 118. Ohnesorge N, Viemann D, Schmidt N, Czymai T, Spiering D, Schmolke M, Ludwig S, Roth J, Goebeler M, and Schmidt M. Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4). *J Biol Chem* 285: 26199–26210, 2010.
 119. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A, Platia E, Feld GK, Akiyama T, Brodsky MA, and Greene HL. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. *J Am Coll Cardiol* 43: 1201–1208, 2004.
 120. Ota H, Eto M, Kano MR, Kahyo T, Setou M, Ogawa S, Iijima K, Akishita M, and Ouchi Y. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. *Arterioscler Thromb Vasc Biol* 30: 2205–2211, 2010.
 121. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, and Colvard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. *Circulation* 110: II45–II49, 2004.
 122. Pasterkamp G and van Lammeren GW. Pleiotropic effects of statins in atherosclerotic disease. *Expert Rev Cardiovasc Ther* 8: 1235–1237, 2010.
 123. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, and Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the AR-MYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. *Circulation* 114: 1455–1461, 2006.
 124. Pelat M, Dessy C, Massion P, Desager JP, Feron O, and Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E^{-/-} mice *in vivo*. *Circulation* 107: 2480–2486, 2003.
 125. Pellegrini CN, Vittinghoff E, Lin F, Hulley SB, and Marcus GM. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. *Heart* 95: 704–708, 2009.
 126. Podzuweit T, Braun W, Muller A, and Schaper W. Arrhythmias and infarction in the ischemic pig heart are not mediated by xanthine oxidase-derived free oxygen radicals. *Basic Res Cardiol* 82: 493–505, 1987.
 127. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, and Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. *Am J Cardiol* 95: 764–767, 2005.
 128. Quist-Paulsen P. Statins and inflammation: an update. *Curr Opin Cardiol* 25: 399–405, 2010.
 129. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, and Macfarlane PW. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. *BMJ* 342: d1250, 2011.
 130. Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, Munz BM, Muller P, Steendijk P, Reil GH, Allessie MA, Bohm M, and Neuberger HR. Aldosterone promotes atrial fibrillation. *Eur Heart J* 33: 2098–2108, 2012.
 131. Reilly SN, Jayaram R, Nahar K, Antoniadis C, Verheule S, Channon KM, Alp NJ, Schotten U, and Casadei B. Atrial sources of reactive oxygen species vary with the duration

- and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. *Circulation* 124: 1107–1117, 2011.
132. Ridker PM, Thuren T, Zalewski A, and Libby P. Interleukin-1 β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). *Am Heart J* 162: 597–605, 2011.
133. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinka A, Hirsch-Hoffmann B, Schwoerer AP, Lau D, Fu X, Klingel K, Sydow K, Didie M, Seniuk A, von Leitner EC, Szoecs K, Schrickel JW, Treede H, Wenzel U, Lewalter T, Nickenig G, Zimmermann WH, Meinertz T, Boger RH, Reichenspurner H, Freeman BA, Eschenhagen T, Ehmke H, Hazen SL, Williams S, and Baldus S. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. *Nat Med* 16: 470–474, 2010.
134. Saffitz JE, Douglas P. Zipes Lecture. Biology and pathobiology of cardiac connexins: from cell to bedside. *Heart Rhythm* 3: 102–107, 2006.
135. Sakabe M, Fujiki A, Sakamoto T, Nakatani Y, Mizumaki K, and Inoue H. Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction. *J Cardiovasc Electrophysiol* 23: 1130–1135, 2012.
136. Sato K, Nuki T, Gomita K, Weyand CM, and Hagiwara N. Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. *Atherosclerosis* 213: 33–39, 2010.
137. Savelieva I, Kakouros N, Kourliouros A, and Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. *Europace* 13: 610–625, 2011.
138. Sawaya SE, Rajawat YS, Rami TG, Szalai G, Price RL, Sivasubramanian N, Mann DL, and Khoury DS. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. *Am J Physiol Heart Circ Physiol* 292: H1561–H1567, 2007.
139. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, Keaney JF, Jr., Wang TJ, Vasan RS, and Benjamin EJ. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. *Am J Cardiol* 104: 92–96, 2009.
140. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, Tofler GH, Selhub J, Jacques PF, Wolf PA, Magnani JW, Ellinor PT, Wang TJ, Levy D, Vasan RS, and Benjamin EJ. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. *Circulation* 121: 200–207, 2010.
141. Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Meli AC, Wronska A, Dura M, Chen BX, and Marks AR. Role of chronic ryanodine receptor phosphorylation in heart failure and beta-adrenergic receptor blockade in mice. *J Clin Invest* 120: 4375–4387, 2010.
142. Shan J, Xie W, Betzenhauser M, Reiken S, Chen BX, Wronska A, and Marks AR. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia. *Circ Res* 111: 708–717, 2012.
143. Shen B, Smith RS, Jr., Hsu YT, Chao L, and Chao J. Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. *J Biol Chem* 284: 35471–35478, 2009.
144. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, and Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. *Cardiovasc Res* 69: 865–875, 2006.
145. Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, and Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. *Circulation* 115: 310–318, 2007.
146. Shiroshita-Takeshita A, Schram G, Lavoie J, and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. *Circulation* 110: 2313–2319, 2004.
147. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, Okkenhaug K, Hagenbeek TJ, Spits H, and Cantrell DA. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. *Nat Immunol* 9: 513–521, 2008.
148. Spach MS and Starmer CF. Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. *Cardiovasc Res* 30: 337–344, 1995.
149. Spodick DH. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. *JAMA* 235: 39–41, 1976.
150. Suleiman M, Koestler C, Lerman A, Lopez-Jimenez F, Herges R, Hodge D, Bradley D, Cha YM, Brady PA, Munger TM, Asirvatham SJ, Packer DL, and Friedman PA. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial. *Heart Rhythm* 9: 172–178, 2012.
151. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, and Shyy JY. Statins activate AMP-activated protein kinase *in vitro* and *in vivo*. *Circulation* 114: 2655–2662, 2006.
152. Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Koike A, Nagashima K, Kirigaya H, Yajima J, Sawada H, Aizawa T, and Yamashita T. Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. *Circ J* 76: 607–611, 2012.
153. Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, Prineas R, Folsom AR, Ambrose M, and Alonso A. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol* 108: 1272–1276, 2011.
154. Tchou GD, Wirka RC, Van Wagoner DR, Barnard J, Chung MK, and Smith JD. Low prevalence of connexin-40 gene variants in atrial tissues and blood from atrial fibrillation subjects. *BMC Med Genet* 13: 102, 2012.
155. Tselentakis EV, Woodford E, Chandy J, Gaudette GR, and Saltman AE. Inflammation effects on the electrical properties of atrial tissue and inducibility of postoperative atrial fibrillation. *J Surg Res* 135: 68–75, 2006.
156. van der Velden HM, Ausma J, Rook MB, Hellemons AJ, van Veen TA, Allesie MA, and Jongsma HJ. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. *Cardiovasc Res* 46: 476–486, 2000.
157. Vermees E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, and Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. *Circulation* 107: 2926–2931, 2003.
158. Villarreal G, Jr., Zhang Y, Larman HB, Gracia-Sancho J, Koo A, and Garcia-Cardena G. Defining the regulation of KLF4 expression and its downstream transcriptional

- targets in vascular endothelial cells. *Biochem Biophys Res Commun* 391: 984–989, 2010.
159. Virani SS, Nambi V, Razavi M, Lee VV, Elayda M, Wilson JM, and Ballantyne CM. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. *Am Heart J* 155: 541–546, 2008.
 160. Wagner AH, Kohler T, Ruckschloss U, Just I, and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. *Arterioscler Thromb Vasc Biol* 20: 61–69, 2000.
 161. Wagner RJ, Martin KA, Powell RJ, and Rzucidlo EM. Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR. *Am J Physiol Cell Physiol* 299: C119–C127, 2010.
 162. Wagner S, Rokita AG, Anderson ME, and Maier LS. Redox regulation of sodium and calcium handling. *Antioxid Redox Signal* 18: 1063–1077, 2013.
 163. Wakili R, Voigt N, Kaab S, Dobrev D, and Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. *J Clin Invest* 121: 2955–2968, 2011.
 164. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, and Isner JM. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. *Circulation* 105: 3017–3024, 2002.
 165. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, and Nickenig G. Cellular antioxidant effects of atorvastatin *in vitro* and *in vivo*. *Arterioscler Thromb Vasc Biol* 22: 300–305, 2002.
 166. Watanabe E. Uric acid and atrial fibrillation—cause or other association? *Circ J* 76: 584–585, 2012.
 167. Wetzel U, Boldt A, Lauschke J, Weigl J, Schirdewahn P, Dorszewski A, Doll N, Hindricks G, Dhein S, and Kottkamp H. Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. *Heart* 91: 166–170, 2005.
 168. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, and Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. *Proc Natl Acad Sci U S A* 93: 8745–8749, 1996.
 169. Wirka RC, Gore S, Van Wagoner DR, Arking DE, Lubitz SA, Lunetta KL, Benjamin EJ, Alonso A, Ellinor PT, Barnard J, Chung MK, and Smith JD. A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation. *Circ Arrhythm Electrophysiol* 4: 87–93, 2011.
 170. Yaktubay Dondas N, Sucu N, Coskun Yilmaz B, Kaplan HM, Ozeren M, Karaca MK, Vezir O, and Singirik E. Molecular mechanism of vasorelaxant and antiatherogenic effects of the statins in the human saphenous vein graft. *Eur J Pharmacol* 666: 150–157, 2011.
 171. Yamashita T, Sekiguchi A, Iwasaki YK, Date T, Sagara K, Tanabe H, Suma H, Sawada H, and Aizawa T. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. *Circ J* 74: 262–270, 2010.
 172. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D, Takuwa Y, Kawada T, Brownlee M, Nishikawa T, and Araki E. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. *Circ Res* 100: 1442–1451, 2007.
 173. Yoshino S, Yoshikawa A, Hamasaki S, Ishida S, Oketani N, Saihara K, Okui H, Kuwahata S, Fujita S, Ichiki H, Ueya N, Iriki Y, Maenosono R, Miyata M, and Tei C. Atrial fibrillation-induced endothelial dysfunction improves after restoration of sinus rhythm. *Int J Cardiol* 168: 1280–1285, 2013.
 174. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboyes T, Bilchik B, and Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. *Am J Cardiol* 92: 1379–1383, 2003.
 175. Zeiser R, Maas K, Youssef S, Durr C, Steinman L, and Negrin RS. Regulation of different inflammatory diseases by impacting the mevalonate pathway. *Immunology* 127: 18–25, 2009.
 176. Zhang M, Perino A, Ghigo A, Hirsch E, and Shah AM. NADPH oxidases in heart failure: poachers or gamekeepers? *Antioxid Redox Signal* 18: 1024–1041, 2013.
 177. Zhou Q and Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives. *Circ J* 74: 818–826, 2010.
 178. Zhou X, Du JL, Yuan J, and Chen YQ. Statins therapy can reduce the risk of atrial fibrillation in patients with acute coronary syndrome: a meta-analysis. *Int J Med Sci* 10: 198–205, 2013.
 179. Zissimopoulos S, Docrat N, and Lai FA. Redox sensitivity of the ryanodine receptor interaction with FK506-binding protein. *J Biol Chem* 282: 6976–6983, 2007.

Address correspondence to:

Prof. Barbara Casadei
Department of Cardiovascular Medicine
University of Oxford
L6, West Wing
John Radcliffe Hospital
Oxford OX3 9DU
United Kingdom

E-mail: barbara.casadei@cardiov.ox.ac.uk

Date of first submission to ARS Central, July 19, 2013; date of acceptance, August 6, 2013.

Abbreviations Used

95% CI = 95% confidence interval
ADMA = asymmetric dimethylarginine
AF = atrial fibrillation
APD = action potential duration
APJ = apelin receptor
BH4 = tetrahydrobiopterin
CaMKII = calmodulin-kinase II
CPB = cardiopulmonary bypass
CRP = C-reactive protein
Cx40 = connexin 40
Cx43 = connexin 43
df = degrees of freedom
HF = heart failure
HMG-CoA = 3-hydroxy-3-methylglutaryl-coenzyme A
HR = hazard ratio
IL = interleukin

Abbreviations Used (Cont.)

KLF2 = kruppel-like factor 2
LA = left atrial
LTCC = L-type Ca channels
MEK = MAP kinase kinase
MPO = myeloperoxidase
MTORC1 = mammalian target of rapamycin complex 1
NO = nitric oxide
NOS = nitric oxide synthase
NOX = NADPH-oxidase
OR = odds ratio
PKA = protein kinase A

PKC = protein kinase C
PPAR = peroxisome proliferator-activated factor
RA = right atrial
Rheb = ras homolog enriched in brain
RLU = relative light units
ROS = reactive oxygen species
RR = relative risk
RyR2 = ryanodine receptor
SMD = standardized mean difference
TGF- β = transforming growth factor β
TNF- α = tumor necrosis factor α
XO = xanthine oxidase